生长抑素（somatostatin，SST）是一种抑制多种激素释放的调节肽，具有广泛的内分泌抑制作用，其类似物在上消化道出血、急性胰腺炎、肢端肥大症等疾病中被广泛使用。虽然美国食品和药物管理局（FDA）将其评为B级药物，并且国内外临床医师对于妊娠合并上述疾病的患者常使用该类药物治疗，但其在人类妊娠期使用的安全性及对母胎的近/远期影响目前尚无定论，有待进一步研究。本文综述近年SST的热点研究，尤其是SST受体在生殖细胞中的表达及其对生育能力的影响。根据国内外的相关研究报道发现，SST及其类似物不仅可改善妊娠期相关疾病的妊娠结局，并且对胎儿和新生儿无明显致畸形的不良反应，为临床工作者妊娠期使用SST类似物治疗疾病时权衡利弊提供了重要的参考依据。%Somatostatin (SST) is a regulatory peptide, inhibiting the release of many hormones, with a wide range of endocrine inhibitory effect on diseases such as upper gastrointestinal bleeding, acute pancreatitis, acromegaly and so on. The FDA has recognized SST analogues as Class B drugs,and the domestic and foreign clinicians often use it to treat the pregnancy-complicated diseases,but the application security of it in human pregnancy is still inconclusive and worth further studying. This paper reviews the recent hot research mechanisms of SST, especially the expression of somatostatin receptor in germ cells and its effect on fertility. And according to the relevant research reports at home and abroad, we found that using the SST and its analogues not only can improve the pregnancy outcomes of related diseases, but also there is no obvious deformity caused by the side effects on the fetus and newborn. This provides an important reference for clinical workers weighing the profits and constrains of somatostatin analogues in the treatment of diseases during pregnancy.
展开▼
